secwatch.observer — SEC 8-K summary
======================================

Issuer:     PROTHENA CORP PUBLIC LTD CO (PRTA)
CIK:        0001559053
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0001559053-25-000022
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prothena Q1 net loss $60.2M, cash $418.8M; AFFIRM-AL data due Q2 2025
---------------------------------------------------------------------

- Net loss $60.2M ($1.12/share) vs $72.2M ($1.34/share) year ago; revenue $2.8M (from BMS collaboration).
- Cash $418.8M at quarter end; FY2025 net cash burn guidance $168-175M, ending cash ~$301M.
- Phase 3 AFFIRM-AL (birtamimab) topline results expected Q2 2025; SPA with FDA, primary endpoint all-cause mortality.
- Multiple PRX012 Phase 1 readouts expected from mid-2025; Roche to decide prasinezumab next steps mid-year.
- Novo Nordisk's coramitug Phase 2 for ATTR-CM completes enrollment; results expected H2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1559053/000155905325000022/0001559053-25-000022-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1559053/000155905325000022/prta-20250508.htm
  HTML page:      https://secwatch.observer/filing/0001559053-25-000022

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer